← Back to all trials
Completed
NCT07940790
A Single-center, Open-label, Non-randomized Pilot Study of add-on Olmesartan 20 mg or 40 mg Daily, With the Dose Chosen According to Blood Pressure at Enrollment as in Routine Practice, Over 9 Months in Patients With Type 2 Diabetes and Albuminuria Who Were Already Receiving an SGLT2i.
Conditions: Type 2 Diabetes Mellitus, Diabetic Kidney Disease, Albuminuria
Sex: All
Ages: 20 Years – 80 Years
Healthy volunteers: No
Phase: NA
Enrollment: 60
Sponsor: Tri-Service General Hospital (TSGH)
Location: Tri-Service General Hospital Taipei
Summary
This study evaluates the efficacy and safety of adding olmesartan to sodium-glucose cotransporter-2 inhibitor (SGLT2i) therapy in patients with type 2 diabetes mellitus and persistent albuminuria. Participants receive olmesartan at a dose of either 20 mg or 40 mg daily in addition to their ongoing SGLT2i treatment. Changes in urinary albumin-to-creatinine ratio (UACR), renal function, and blood pressure are assessed over a 9-month follow-up period. The study aims to evaluate the potential additional renoprotective effects of olmesartan in patients with type 2 diabetes who continue to have albuminuria despite SGLT2i therapy.
Eligibility Criteria
Inclusion Criteria:
* Type 2 diabetes mellitus.
* Receiving sodium-glucose cotransporter-2 inhibitor therapy.
* With persistent albuminuria
* Willing and able to provide written informed consent.
Exclusion Criteria:
* Known hypersensitivity or history of severe adverse reactions to other angiotensin receptor blockers (ARBs).
* Active liver disease or severe hepatic impairment (Aspartate transaminase \[AST\] \> 3 × ULN \[upper limit of normal\]; Alanine transaminase \[ALT\] \> 3 × ULN).
* Moderate-to-severe renal impairment (estimated GFR \< 30 mL/min/1.73 m²).
* Women who are pregnant or currently breastfeeding.
* Judged by the study investigator to be unsuitable for participating (or continuing) in this trial.
Source: ClinicalTrials.gov (NCT07940790). StuddyBuddy aggregates publicly available trial information.